TABLE 1.
1,079 patient characteristics and their effects on plasma concentration of ATV.
| Characteristics | Value N (%) or mean ± SD | Plasma ATV concentration, ng/mL | ||||
|---|---|---|---|---|---|---|
| Univariable analysis | Multivariable analysis | |||||
| Estimate | p-value | Estimate | p-value | |||
| Demographic data | ||||||
| Total number | 1,079 | |||||
| Age (years) | 62.95 ± 10.07 | 0.010 | 1.02E−02 | |||
| Sex | Female | 218 (20.20) | 0.029 | 7.63E−01 | ||
| Male | 861 (79.80) | |||||
| Dosage (mg) | 10 | 19 (1.76) | 0.017 | 2.13E−03 | 0.014 | 2.69E−02 |
| 20 | 924 (85.63) | |||||
| 40 | 136 (12.60) | |||||
| Medical history | ||||||
| Arrhythmia | No | 984 (91.38) | −0.158 | 2.43E−01 | ||
| Yes | 93 (8.62) | |||||
| Diabetes | No | 779 (72.33) | −0.014 | 8.70E−01 | ||
| Yes | 298 (27.67) | |||||
| Heart failure | No | 986 (91.55) | −0.182 | 1.82E−01 | ||
| Yes | 91 (8.45) | |||||
| Hypertension | No | 432 (40.07) | 0.044 | 5.73E−01 | ||
| Yes | 646 (59.93) | |||||
| Hyperlipidemia | No | 956 (88.68) | 0.054 | 6.51E−01 | ||
| Yes | 122 (11.32) | |||||
| Biochemical measurements | ||||||
| ALT, U/L | 27.50 ± 13.37 | 0.010 | 1.13E−03 | |||
| AST, U/L | 26.77 ± 11.29 | 0.020 | 6.44E−09 | 0.021 | 1.80E−04 | |
| CREA, umol/L | 86.37 ± 24.87 | 0.006 | 2.99E−04 | 0.004 | 3.47E−04 | |
| eGFR, ml/min/1.73m2 | 94.24 ± 72.49 | −0.001 | 8.50E−02 | |||
| CK, U/L | 111.95 ± 110.51 | 0.000 | 4.07E−01 | |||
| CKMB, U/L | 7.55 ± 6.03 | 0.001 | 9.20E−01 | |||
| CHOL, mmol/L | 4.29 ± 1.13 | 0.093 | 6.44E−03 | |||
| LDL-C, mmol/L | 2.59 ± 0.93 | 0.133 | 1.26E−03 | |||
| HDL-C, mmol/L | 0.96 ± 0.26 | −0.314 | 3.67E−02 | |||
| TRIG, mmol/L | 1.61 ± 1.11 | 0.042 | 2.23E−01 | |||
| GLUC, mmol/L | 6.73 ± 2.74 | 0.015 | 2.90E−01 | |||
| Lpa, mmol/L | 303.24 ± 324.14 | 0.000 | 1.89E−01 | |||
| Apo (a), g/L | 1.04 ± 0.27 | −0.451 | 3.34E−03 | |||
| Medication | ||||||
| β-blockers | No | 114 (10.58) | 0.023 | 8.52E−01 | ||
| Yes | 963 (89.42) | |||||
| ACEIs | No | 390 (36.21) | −0.081 | 3.07E−01 | ||
| Yes | 687 (63.79) | |||||
| CCBs | No | 775 (71.96) | 0.096 | 2.56E−01 | ||
| Yes | 302 (28.04) | |||||
| PPI | No | 552 (51.25) | 0.085 | 2.65E−01 | ||
| Yes | 525 (48.75) | |||||
Estimates were calculated by applying a linear regression model. Variables with p < 0.05 were included into the multivariable analysis. SD = standard deviation; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CK = creatine kinase; eGFR = estimated glomerular filtration rate; CKMB = creatine kinase MB; CHOL = cholesterol; LDL-C = low density lipoprotein cholesterol; HDL-C = high density lipoprotein cholesterol; TRIG = triglyceride; GLUC = glucose; Lpa = lipoprotein (a); Apo (a) = apolipoprotein (a); ACEIs = angiotensin converting enzyme inhibitors; CCBs = calcium channel blockers; PPIs = proton pump inhibitors.